(Reuters) - Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant ...
Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, ...
Britain's drugs cost-effectiveness watchdog NICE said on Thursday it will recommend Eli Lilly's obesity drug Mounjaro be made ...
ELI Lilly is spending another US$3 billion to build out its US manufacturing footprint as it ramps up production of its ...
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
That criteria makes 3.4 million patients in England eligible for the treatment, but over the next three years, access will be restricted to about 220,000 people with the “highest clinical need” – or 6 ...
U.S. Food and Drug Administration Commissioner Robert Califf defended the agency's role in addressing the country's obesity ...
The U.K. will soon offer Eli Lilly's Mounjaro for people with obesity — but only to a small share of those medically eligible ...
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
The U.K. will start offering Eli Lilly’s weight loss drug next year, but will restrict the medicine to people with the ...
Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care ...
Wall Street is chewing over data on Amgen’s weight loss injection, MariTde. Meanwhile, GE HealthCare will acquire a Japanese ...